Rapid-Onset Subfulminant Liver Failure Associated with Troglitazone
Authors: Sanjay Jagannath, Rudra Rai
Journal: Annals of Internal Medicine (2000)

Letters18 April 2000Rapid-Onset Subfulminant Liver Failure Associated with TroglitazoneSanjay Jagannath, MD and Rudra Rai, MDSanjay Jagannath, MDThe Johns Hopkins Hospital; Baltimore, MD 21287 (Jagannath)The Johns Hopkins Hospital; Baltimore, MD 21287 (Rai)Search for more papers by this author and Rudra Rai, MDThe Johns Hopkins Hospital; Baltimore, MD 21287 (Jagannath)The Johns Hopkins Hospital; Baltimore, MD 21287 (Rai)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-8-200004180-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Troglitazone (Rezulin, Parke-Davis, Morris Plains, New Jersey) is the first thiazolidineodione approved for use as an initial agent and in conjunction with sulfonylureas in managing type 2 diabetes (1). However, troglitazone has been associated with hepatotoxicity. U.S. Food and Drug Administration (FDA) recommendations on the frequency of routine liver function testing for detection of troglitazone hepatotoxicity have been revised five times in the past 2 years, with each successive revision more stringent than the previous. The most recent FDA recommendation was to withdraw approval of troglitazone as monotherapy for type 2 diabetes but to continue supporting use ...References1. Imura H. A novel antidiabetic drug, troglitazone—reason for hope and concern. N Engl J Med. 1998;338:908-9. CrossrefMedlineGoogle Scholar2. Willman D. FDA advised to restrict Rezulin use for diabetes. Los Angeles Times Special Reports. March 27, 1999. Google Scholar3. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-8. LinkGoogle Scholar4. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al . Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med. 1998;129:38-41. LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Sanjay Jagannath, MD; Rudra Rai, MDAffiliations: The Johns Hopkins Hospital; Baltimore, MD 21287 (Jagannath)The Johns Hopkins Hospital; Baltimore, MD 21287 (Rai) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAnalytical and Omics-Based Advances in the Study of Drug-Induced Liver InjuryThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and futureDrug-Induced Liver DiseaseImportant Elements for the Diagnosis of Drug-Induced Liver InjuryLiver Disease Caused by DrugsHow safe is the use of thiazolidinediones in clinical practice?Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazoneHepatic ToxicologyComparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazoneTroglitazone and liver injury: In search of answersHepatotoxicity of thiazolidinedionesTroglitazone-induced liver failure: a case studyIncidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone“Did This Drug Cause My Patient's Hepatitis?” and Related QuestionsDavid W. Nierenberg, MDHepatotoxicity of thiazolidinedionesPathology of the liverDrug-induced liver diseaseAcute liver failureAssessing causality in drug-induced liver injury 18 April 2000Volume 132, Issue 8Page: 677KeywordsDrugsFood and Drug AdministrationHepatitisLiverLiver diseasesLiver transplantationPlasma cellsTherapeutic drug monitoringType 2 diabetesVomiting ePublished: 15 August 2000 Issue Published: 18 April 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...